Evidence map›Paper›PMID 35476113›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors.

Caroline Seo, Erica Horodniceanu, Rachel Shah, Grace Goldstein, David Ray, Bonita Bennett, Alexandria Phan, Kelly McCarrier

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Caroline SeoPharmerit-an OPEN Health Company, 4350 East West Highway, Suite 1100, Bethesda, MD, USA.
Erica HorodniceanuPharmerit-an OPEN Health Company, 4350 East West Highway, Suite 1100, Bethesda, MD, USA.
Rachel ShahPharmerit-an OPEN Health Company, 4350 East West Highway, Suite 1100, Bethesda, MD, USA.
Grace GoldsteinThe Carcinoid Cancer Foundation, Mt. Kisco, NY, USA.
David RayIpsen Biopharmaceuticals, Cambridge, MA, USA.
Bonita BennettAbramson Cancer Center, Philadelphia, PA, USA.
Alexandria PhanUT Health East Texas North Campus MD Anderson Cancer Center, Tyler, TX, USA.
Kelly McCarrierPharmerit-an OPEN Health Company, 4350 East West Highway, Suite 1100, Bethesda, MD, USA. KellyMcCarrier@openhealthgroup.com.
Pharmerit (United States) · USAbramson Cancer CenterCarcinoid Cancer Foundation · USThe University of Texas Health Science Center at Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNeuroendocrine tumors (NETs) negatively impact patients' quality of life. Octreotide long-acting release (LAR) and lanreotide depot are somatostatin analogs (SSAs) approved to treat NETs. The study objective was to explore SSA treatment experiences and preferences of patients with NETs.

methodsQualitative interviews were conducted in US adults (≥ 21 years) with NETs who had ≥ 6 months' treatment with each SSA and transitioned from octreotide LAR to lanreotide depot within the previous year. Participants were asked open-ended questions about their experiences with octreotide LAR and lanreotide depot, treatment preferences, and SSA treatment attributes.

resultsTwenty participants (mean age: 58 years; 90% female; 85% white) completed interviews. The most common reasons for treatment transition were doctor recommendation (70%), treatment not working as expected (55%), and injection type preference (45%). Participants reported 34 unique favorable attributes of SSA treatment and 82 unique unfavorable attributes. Symptom control was the most frequently reported favorable attribute (associated with octreotide LAR by 60% of participants and lanreotide depot by 65%). Painful injection (65%) was most frequently cited unfavorable attribute for octreotide LAR and injection experience dependent on administrator (35%) for lanreotide depot. The three SSA treatment attributes rated as most important were side effects, symptom control, and ability to stabilize tumor.

conclusionOur qualitative data provide valuable insight into the treatment attributes that patients with NETs consider important when making SSA treatment decisions. Factors related to injection administration, side effects, and symptom control are important to patients and should be included in patient-provider communications in clinical contexts.

Indexed as

Neuroendocrine TumorsFemaleHumansMaleMiddle AgedOctreotideQuality of LifeSomatostatinOctreotideSomatostatinNeuroendocrine tumorsPatient experiencePatient preferenceQualitative researchSomatostatin analogs

Identifiers

PMID35476113
PMCPMC9135819
OpenAlexW4225009153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.